[Congressional Record Volume 171, Number 68 (Monday, April 21, 2025)]
[Extensions of Remarks]
[Page E328]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                RECOGNIZING SCLERODERMA AWARENESS MONTH

                                 ______
                                 

                        HON. TIMOTHY M. KENNEDY

                              of new york

                    in the house of representatives

                         Monday, April 21, 2025

  Mr. KENNEDY of New York. Mr. Speaker, I rise today to recognize 
Scleroderma Awareness Month, an important commemoration dedicated to 
increasing public understanding and awareness of Scleroderma, a chronic 
autoimmune disease that impacts approximately 300,000 individuals 
across the United States. Scleroderma, meaning ``hard skin,'' is a rare 
autoimmune disease characterized by the abnormal growth of connective 
tissue, leading to skin thickening and potential involvement of 
internal organs, which can result in serious complications.
  Each June, we unite with the brave patients, families, and devoted 
healthcare professionals who work tirelessly to advocate for research, 
treatment, and support for those affected by scleroderma. This month 
not only serves as a time of recognition but also as a call to action 
to advance our commitment to finding a cure for this debilitating 
disease.
  Organizations such as the Scleroderma Foundation, the Scleroderma 
Research Foundation, and the Scleroderma Family Registry and DNA 
Repository lead the way in research and patient advocacy, providing 
hope and meaningful support to those impacted. Through public awareness 
campaigns, educational programs, and patient-focused initiatives, these 
organizations are making great progress in increasing awareness and 
advancing scientific breakthroughs.
  Despite these efforts, there is still much work to be done. Many 
patients experience delayed diagnoses due to a lack of awareness and 
limited understanding of this complex disease. Enhancing diagnostic 
tools, boosting research funding, and expanding access to care are 
crucial for improving patient outcomes.
  Today, I stand to amplify the voices of scleroderma patients and 
their families. We must continue to support efforts that promote 
research, education, and compassionate care for those impacted by this 
disease. it is my hope that through our collective efforts, we can 
bring much-needed awareness and resources to the fight against 
scleroderma, ultimately improving the lives of those affected and 
bringing us closer to a cure.

                          ____________________